Merck Sharp and Dohme presents new HIV data at CROI 2018

Merck Sharp and Dohme is attending this week's Conference on Retroviruses and Opportunistic Infections (CROI), where it is presenting new HIV drug research insights.

The conference, which runs from March 4th to 7th in Boston, Massachusetts, will see Merck sharing data from studies generated through its robust HIV pipeline, including data on the late-stage investigational non-nucleoside reverse transcriptase inhibitor doravirine.

Also under discussion will be MK-8591, a new nucleoside reverse transcriptase translocation inhibitor offering a first-of-its-kind mechanism that will soon be commencing clinical trials.

In addition, Merck scientists will present data from experiments investigating the mechanisms of formation and maintenance of HIV reservoirs, and the impact of HIV persistence in the gut on immune recovery during antiretroviral therapy.

Dr George Hanna, associate vice-president for clinical research at Merck Research Laboratories, said: "Merck's commitment to HIV has never wavered, and we are very excited about the progress being made in our labs today to both better understand HIV and to bring forward the next generation of potential treatments."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.